Login to Your Account

Apeiron steps in with EU neuroblastoma nod as United exits market

By Cormac Sheridan
Staff Writer

Friday, May 12, 2017

DUBLIN – Apeiron Biologics AG gained formal European Commission approval last week for dinutuximab beta as a treatment for pediatric neuroblastoma, a historic milestone for the Austrian biotech company and one that puts it on a firm financial footing.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription